Skip to content

Trump Announces Deal With Moderna for 100 Million Doses of Potential CCP Virus Vaccine

French Privacy Watchdog Opens Preliminary Investigation Into TikTok

PARIS—France’s data privacy watchdog CNIL said on Tuesday that it has opened a preliminary investigation into Chinese-owned video-sharing app TikTok after it received a complaint. TikTok, owned by China’s ByteDance, is already under investigation over privacy concerns by U.S., European Union and Dutch authorities. “A complaint about TikTok was received in May. This complaint is now under investigation,” a CNIL spokesman said, confirming a Bloomberg report. He declined to elaborate on the nature of the complaint or the identity of the plaintiff. In the United States, officials have said that TikTok poses a national security risk because of the personal data it handles. President Donald Trump has threatened to ban TikTok and has given ByteDance 45 days to negotiate a sale of TikTok’s U.S. operations to Microsoft. In June, the…

Trump Announces Deal With Moderna for 100 Million Doses of Potential CCP Virus Vaccine

The Trump administration has struck a deal with Massachusetts-based drugmaker Moderna to secure 100 million doses of its potential CCP virus vaccine.

“This evening I’m pleased to announce that we have reached an agreement with Moderna to manufacture and deliver 100 million doses of their coronavirus vaccine candidate. The federal government will own these vaccine doses, we’re buying them,” President Donald Trump announced at a White House press briefing on Tuesday.

The deal is valued at up to $1.525 billion for the company to manufacture and deliver 100 million doses of its vaccine candidate. The $1.525 billion includes “incentive payments for timely delivery of the product.”

“The U.S. government has announced that consistent with its commitment to free access to COVID-19 vaccines, Americans will receive mRNA-1273 at no cost for the vaccine itself,” Moderna announced in a release. “As is customary with government-purchased vaccines, healthcare professionals could charge for the cost of administering the vaccine.”

Moderna’s price per dose comes to around $30.50 per person for a two-dose regimen. Its vaccine candidate, mRNA-1273, is one of the few that have already advanced to phase 3, the final stage of testing, and is on track to be completed in September, the company said this month.

Under the agreement, the U.S. government will also have the option to purchase another 400 million doses of the vaccine candidate from Moderna.

The U.S. government previously awarded the company up to $955 million to fund its research, bringing the total funding聽for early access to mRNA-1273 to聽up to $2.48 billion.

Trump Announces Deal With Moderna for 100 Million Doses of Potential CCP Virus Vaccine President Donald Trump speaks during a news conference at the White House in Washington on Aug. 11, 2020. (Alex Wong/Getty Images)

Trump said that the administration has also secured partnerships with聽Johnson and Johnson, Sanofi, and聽GlaxoSmithKline to support the large scale manufacturing of the vaccine candidates.

“Three vaccine candidates are now in phase 3 trials already, the final stage of clinical trials. We are investing in the development and manufacture of the top six vaccine candidates to ensure rapid delivery,” Trump said. “The military is ready to go. They’re ready to deliver a vaccine to Americans as soon as one is fully approved by the [Food and Drug Administration] and we’re moving very close to that approval.”

The deals are part of the U.S. government’s Operation Warp Speed鈥攁 national effort to quickly develop and deliver a safe and effective vaccine and therapeutics to combat the CCP (Chinese Communist Party) virus, also known as the novel coronavirus. The operation involves partnerships between the U.S. government, the scientific community, and the private sector.

鈥淯nder Operation Warp Speed, we鈥檝e shaved years off of the time that it takes to develop a vaccine and we鈥檝e done it while maintaining the FDA gold standard for safety,” Trump said in a statement.

With the exception of its deal with AstraZeneca, which offered a lower price per drug in exchange for upfront research and development costs, all the deals price COVID-19 vaccines between $20 to $42 for a two-dose course of treatment.

Reuters contributed to this report.

Follow Mimi on Twitter: @MimiNguyenLy

Focus News: Trump Announces Deal With Moderna for 100 Million Doses of Potential CCP Virus Vaccine

Kodak Shares Drop After Loan Paused Amid Insider Trading Allegations

The agency had signed a letter of interest with Eastman Kodak on July 28 to provide the company with a $765 million loan. President Donald Trump announced the deal on the same day. The federal loan was intended to launch Kodak Pharmaceuticals to produce active pharmaceutical ingredients for generic drugs, to help reduce the United States’s reliance on other countries. The deal marked Trump’s 33rd use of the Defense Production Act. Kodak shares skyrocketed more than 1,100 percent just two days after the deal’s July 28 announcement. It reached a high of $60 a share on July 29. Kodak shares closed at $14.88 on Friday, and at $10.73 by Monday. Sen. Elizabeth Warren (D-Mass.) sent a letter on Aug. 3 asking the U.S. Securities and Exchange Commission (SEC), an independent U.S. government agency that regulates…